Looking for more Scientific Resources

The William Guy Forbeck Research Foundation is working with the scientific community to shortening the cancer research timetable.

Forbeck Foundation Gets Recognized in Former Scholar Publication!

June 24, 2014

The Forbeck Foundation strives to achieve collaborations between medical professionals.  It is hard to quantify the accomplishments of the Forbeck Foundation because of the vast number of participants and publications.  Collaborations and papers like this frequently result from Forbeck meetings but we don’t always hear about them.  Thank you to Chang-Hyuk for sharing this paper.

Don’t forget to choose the William Guy Forbeck Research Foundation as your charity of choice on Smile.Amazon.com!

June 9, 2014

Don’t forget to choose the William Guy Forbeck Research Foundation as your charity of choice on Smile.Amazon.com! To celebrate Father’s Day, from now through 6/15/2014, the AmazonSmile Foundation will donate an extra $5 for each customer who makes an eligible purchase at smile.amazon.com in support of William Guy Forbeck Research Foundation. This is in addition

Proof of Concept

June 4, 2014

The Forbeck Foundation strives to achieve collaborations between clinicians and researchers to advance cancer research. 2011 Forum participantsChristopher J. Kemp, PhD and Ari Melnick, MD recently published a paper in Cell Reports, May 2014 issue, titled CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer. Kemp and Melnick met at the Forbeck Forum on Epigenetics.

2014 ANR in Cologne, Germany

May 22, 2014

The bi-annual meeting of ANR (Advances in Neuroblastoma Research) was held in Cologne, Germany in May. John Kemshead and Jennifer Forbeck attended on behalf of the Foundation. During ANR the Foundation was recognized for 29 years of work on the Neuroblastoma Staging and Response system which has led to the initial Staging System used for

New Collaboration Unites Industry and Clinic to Develop Novel Neuroblastoma Therapy

July 24, 2013

Kolltan Pharmaceuticals, Inc., a New Haven, CT based private biotech company, has partnered with The Children’s Hospital of Philadelphia (CHOP) to develop a new drug approach for the treatment of neuroblastoma, the most common childhood cancer outside of brain cancer. 650 new cases of neuroblastoma are diagnosed per year in the US, and and there